United Therapeutics (NASDAQ:UTHR) Rating Reiterated by HC Wainwright

United Therapeutics (NASDAQ:UTHR)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $300.00 price target on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 17.58% from the stock’s current price.

A number of other research firms also recently weighed in on UTHR. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. SVB Leerink initiated coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. Wells Fargo & Company raised their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $294.25.

United Therapeutics Price Performance

United Therapeutics stock opened at $255.14 on Thursday. The company has a market capitalization of $11.32 billion, a price-to-earnings ratio of 12.86 and a beta of 0.54. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average is $234.62 and its 200-day moving average is $228.81.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. During the same period in the prior year, the company earned $2.67 earnings per share. The company’s quarterly revenue was up 25.1% on a year-over-year basis. Equities research analysts expect that United Therapeutics will post 23.45 EPS for the current year.

Insider Activity at United Therapeutics

In related news, Director Christopher Patusky sold 1,680 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the sale, the director now owns 4 shares in the company, valued at $896. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Christopher Patusky sold 1,680 shares of United Therapeutics stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total transaction of $376,320.00. Following the transaction, the director now owns 4 shares in the company, valued at approximately $896. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $237.80, for a total transaction of $77,285.00. Following the transaction, the director now owns 5,373 shares in the company, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Insiders sold 138,190 shares of company stock valued at $32,643,561 over the last 90 days. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. Access Investment Management LLC lifted its position in shares of United Therapeutics by 137.2% in the 1st quarter. Access Investment Management LLC now owns 7,210 shares of the biotechnology company’s stock worth $1,656,000 after purchasing an additional 4,170 shares during the period. GLOBALT Investments LLC GA purchased a new stake in shares of United Therapeutics in the 1st quarter worth approximately $207,000. Capstone Investment Advisors LLC lifted its position in shares of United Therapeutics by 90.9% in the 1st quarter. Capstone Investment Advisors LLC now owns 5,062 shares of the biotechnology company’s stock worth $1,163,000 after purchasing an additional 2,410 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of United Therapeutics by 2.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 8,960 shares of the biotechnology company’s stock worth $2,058,000 after purchasing an additional 201 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of United Therapeutics in the 1st quarter worth approximately $2,871,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.